Stay updated on COR388 for AD: Phase 2/3 Clinical Trial
Sign up to get notified when there's something new on the COR388 for AD: Phase 2/3 Clinical Trial page.

Latest updates to the COR388 for AD: Phase 2/3 Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2. This appears to be a minor backend/version update with no visible changes to study details or page content.SummaryDifference0.0%

- Check19 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1, indicating a minor maintenance update with no changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check27 days agoChange DetectedAdded a glossary display option and updated QC/versioning labels to 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0'. Removed the older label 'Last Update Submitted that met QC Criteria', the data label 'No FEAR Act data', and the older 'Revision: v3.3.4'.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision banner updated to v3.3.4, replacing v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check62 days agoChange DetectedThe Study Details page adds a comprehensive list of trial locations by state and country (Arizona, California, Florida, Georgia, Idaho, Illinois, Kansas, Massachusetts, Mississippi, Nevada, New Jersey, New Mexico, New York, North Carolina, Ohio, Oregon, Pennsylvania, Texas, Virginia, Washington, Wisconsin; Cedex; Gipuzkoa; Birmingham; London; Science Park; UK) and replaces older location blocks with an updated geography (Revision: v3.3.3).SummaryDifference2%

- Check91 days agoChange DetectedRevision: v3.3.2 is now shown, replacing Revision: v3.2.0.SummaryDifference0.0%

Stay in the know with updates to COR388 for AD: Phase 2/3 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the COR388 for AD: Phase 2/3 Clinical Trial page.